Full Characterization Of Enoxaparin Necessary For ANDA Approval, Momenta Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Momenta maintains that unless Amphastar and Teva can fully characterize enoxaparin, their generic versions of Aventis' Lovenox will not receive approval
You may also be interested in...
Sandoz Continues Momentum From Omnitrope Decision With Momenta Partnership
Momenta’s characterization technology could facilitate manufacture of follow-on biologics.
Sandoz Continues Momentum From Omnitrope Decision With Momenta Partnership
Momenta’s characterization technology could facilitate manufacture of follow-on biologics.
Andrx Picks Up Lovenox Generic Marketing Rights From Amphastar
Under the $10 mil. deal, Andrx obtains rights to market two strengths of the injectable antithrombotic in the U.S. retail pharmacy market. Amphastar will be responsible for ongoing enoxaparin patent litigation with Sanofi-Aventis. The 30-month stay on Amphastar’s ANDA runs through February 2006.